Dinu Valentin Balanescu

Average (ratings) Keywords Pulmonary embolism, catheter-based therapies, ultrasound-facilitated catheter-directed thrombolysis, anticoagulation, HI-PEITHO, Received: 20 April 2026 Accepted: 22 April 2026 Published online: 15 June 2026 Disclosure: RB has equity interest in Thrombolex Inc and received National Heart, Lung, and Blood Institute funding. All other authors have no conflicts of interest to declare.

Highlights • Cancer therapies after AVR for severe AS can be started sooner in TAVR versus SAVR. • TAVR may improve CV survival of cancer patients with symptomatic severe AS. • Cancer therapies do not appear to negatively impact aortic bioprostheses function. • Time to cancer therapy after AVR for severe AS may be a important valid parameter.

Highlights • Cancer patients with AMI often have standard cardiac treatment deferred. • We analyzed outcomes after medical and invasive management in a cancer population. • Standard cardiac treatment should be considered regardless of cancer stage. • Invasive therapies within 72 h of admission for AMI have survival benefits. Abstract Background The benefits of invasive versus noninvasive management in oncology patients with acute myocardial infarction (AMI) are unclear.